PE20141515A1 - Procedimiento de formulacion de una vacuna que contiene al menos dos antigenos susceptibles de adsorberse en oxihidroxido de aluminio - Google Patents

Procedimiento de formulacion de una vacuna que contiene al menos dos antigenos susceptibles de adsorberse en oxihidroxido de aluminio

Info

Publication number
PE20141515A1
PE20141515A1 PE2014001091A PE2014001091A PE20141515A1 PE 20141515 A1 PE20141515 A1 PE 20141515A1 PE 2014001091 A PE2014001091 A PE 2014001091A PE 2014001091 A PE2014001091 A PE 2014001091A PE 20141515 A1 PE20141515 A1 PE 20141515A1
Authority
PE
Peru
Prior art keywords
alooh
hbsag
adsorbing
procedure
aluminum oxyhydroxide
Prior art date
Application number
PE2014001091A
Other languages
English (en)
Inventor
Landry Bertaux
Isabelle Chacornac
;On Alain Fran&
Jean-Fran& ;Ois Hau
Graf Sandrine Lentsch
Original Assignee
Sanofi Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur filed Critical Sanofi Pasteur
Publication of PE20141515A1 publication Critical patent/PE20141515A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/00034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

SE REFIERE A UNA COMPOSICION DE VACUNA LIQUIDA QUE COMPRENDE: A) OXIHIDROXIDO DE ALUMINIO (AlOOH); B) UN ANTIGENO DE SUPERFICIE DE HEPATITIS B (HBsAg); C) UN ANTIGENO DE HAEMOPHILUS INFLUENZAE TIPO B (Hib) CONSTITUIDO POR POLISACARIDO CAPSULAR CONJUGADO EN UNA PROTEINA PORTADORA TAL COMO PROTEINA TETANICA (PRP-T); Y D) ANTIGENOS DE DIFTERIA, TETANOS, POLIOMIELITIS Y TOS FERINA. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE PREPARACION DE DICHA VACUNA QUE COMPRENDE i) ADSORBER EL ANTIGENO DE SUPERFICIE DE HEPATITIS B EN AlOOH PARA OBTENER UN COMPLEJO AlOOH/HBsAg, Y ii) MEZCLAR DICHO COMPLEJO AlOOH/HBsAg CON EL ANTIGENO DE Hib EN PRESENCIA DE AMINOACIDOS CATIONICOS CON UNA CONCENTRACION DE 100 mg/ml Y DE IONES FOSFATO CON UNA CONCENTRACION DE 35 A 45 mMol/l
PE2014001091A 2012-01-17 2013-01-17 Procedimiento de formulacion de una vacuna que contiene al menos dos antigenos susceptibles de adsorberse en oxihidroxido de aluminio PE20141515A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1250464A FR2985663B1 (fr) 2012-01-17 2012-01-17 Procede de formulation d'un vaccin contenant au moins deux antigenes susceptibles de s'adsorber sur de l'oxy hydroxyde d'aluminium

Publications (1)

Publication Number Publication Date
PE20141515A1 true PE20141515A1 (es) 2014-11-04

Family

ID=47714410

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014001091A PE20141515A1 (es) 2012-01-17 2013-01-17 Procedimiento de formulacion de una vacuna que contiene al menos dos antigenos susceptibles de adsorberse en oxihidroxido de aluminio

Country Status (34)

Country Link
US (1) US9358294B2 (es)
EP (1) EP2804628B1 (es)
JP (2) JP6199310B2 (es)
KR (1) KR102019848B1 (es)
CN (1) CN104039348B (es)
AP (1) AP2014007848A0 (es)
AR (1) AR089737A1 (es)
AU (1) AU2013210927B2 (es)
BR (1) BR112014017416B1 (es)
CA (1) CA2861304C (es)
CR (1) CR20140356A (es)
CY (1) CY1119206T1 (es)
DK (1) DK2804628T3 (es)
EA (1) EA026058B1 (es)
ES (1) ES2625011T3 (es)
FR (1) FR2985663B1 (es)
GE (1) GEP201706642B (es)
GT (1) GT201400120A (es)
HK (1) HK1204293A1 (es)
HR (1) HRP20170692T1 (es)
HU (1) HUE032539T2 (es)
IL (1) IL233643A (es)
LT (1) LT2804628T (es)
MX (1) MX349411B (es)
NZ (1) NZ627345A (es)
PE (1) PE20141515A1 (es)
PH (1) PH12014501546B1 (es)
PL (1) PL2804628T3 (es)
PT (1) PT2804628T (es)
RS (1) RS55962B1 (es)
SI (1) SI2804628T1 (es)
UA (1) UA113000C2 (es)
WO (1) WO2013107988A1 (es)
ZA (1) ZA201405431B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106075428A (zh) * 2015-07-01 2016-11-09 北京科兴中维生物技术有限公司 一种免疫原性组合物及其制备方法
WO2021176409A1 (en) 2020-03-05 2021-09-10 Sanofi Healthcare India Private Limited Preservative combination for vaccine composition
EP4327820A1 (en) 2021-04-20 2024-02-28 KM Biologics Co., Ltd. Liquid sextuple vaccine composition

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0835663T3 (da) * 1992-05-23 2010-02-01 Glaxosmithkline Biolog Sa Kombinerede vacciner omfattende Hepatitis B overfladeantigen og andre antigener
US6790445B1 (en) * 1997-02-06 2004-09-14 Merck & Co., Inc. Preservatives for vaccines
ATE470434T1 (de) * 1997-02-06 2010-06-15 Merck Sharp & Dohme Thimerosal-freie konservierungsmittel für impfstoffe
DK1028750T3 (da) * 1997-09-15 2006-05-22 Sanofi Pasteur Msd Fremgangsmåde til fremstilling af multivalente vacciner
EP1409013B1 (en) * 2001-07-26 2009-11-18 Novartis Vaccines and Diagnostics S.r.l. Vaccines comprising aluminium adjuvants and histidine
GB0118249D0 (en) * 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
CA2456713A1 (en) 2001-08-07 2003-02-20 Antonio Sereno Improved pharmaceutical composition containing a ppar alpha agent and a process for preparing it
FR2828406B1 (fr) * 2001-08-08 2005-06-24 Aventis Pasteur Composition vaccinale bivalente havi
GB0610140D0 (en) * 2006-05-22 2006-06-28 Insense Ltd Protein stability
PE20100366A1 (es) * 2008-10-24 2010-05-21 Panacea Biotec Ltd Novedosas composiciones de vacuna con tos ferina acelular asi como el metodo para su elaboracion

Also Published As

Publication number Publication date
LT2804628T (lt) 2017-05-25
WO2013107988A1 (fr) 2013-07-25
AP2014007848A0 (en) 2014-08-31
JP2017203043A (ja) 2017-11-16
JP6199310B2 (ja) 2017-09-20
GEP201706642B (en) 2017-03-27
MX349411B (es) 2017-07-27
SI2804628T1 (sl) 2017-06-30
PH12014501546A1 (en) 2014-10-08
AU2013210927A1 (en) 2014-08-28
US9358294B2 (en) 2016-06-07
EA201491387A1 (ru) 2014-12-30
ES2625011T3 (es) 2017-07-18
CN104039348B (zh) 2016-05-11
HK1204293A1 (en) 2015-11-13
BR112014017416B1 (pt) 2022-08-16
FR2985663B1 (fr) 2015-03-27
GT201400120A (es) 2015-09-17
JP6356886B2 (ja) 2018-07-11
EA026058B1 (ru) 2017-02-28
CA2861304C (fr) 2021-05-25
CR20140356A (es) 2014-08-28
BR112014017416A2 (pt) 2021-05-25
CA2861304A1 (fr) 2013-07-25
PT2804628T (pt) 2017-04-21
UA113000C2 (uk) 2016-11-25
NZ627345A (en) 2016-07-29
AR089737A1 (es) 2014-09-10
JP2015504085A (ja) 2015-02-05
IL233643A (en) 2017-04-30
IL233643A0 (en) 2014-08-31
KR20140119109A (ko) 2014-10-08
RS55962B1 (sr) 2017-09-29
US20140370049A1 (en) 2014-12-18
BR112014017416A8 (pt) 2017-07-04
EP2804628A1 (fr) 2014-11-26
DK2804628T3 (en) 2017-05-22
PL2804628T3 (pl) 2017-08-31
HUE032539T2 (hu) 2017-10-30
KR102019848B1 (ko) 2019-09-09
CY1119206T1 (el) 2018-02-14
FR2985663A1 (fr) 2013-07-19
EP2804628B1 (fr) 2017-03-01
CN104039348A (zh) 2014-09-10
ZA201405431B (en) 2015-12-23
PH12014501546B1 (en) 2014-10-08
HRP20170692T1 (hr) 2017-07-14
MX2014007850A (es) 2014-08-21
AU2013210927B2 (en) 2017-02-23

Similar Documents

Publication Publication Date Title
NZ734892A (en) Amatoxin-antibody conjugates
MX2009001412A (es) Vacunas de matriz de proteinas y metodos de hacer y administrar tales vacunas.
PE20100366A1 (es) Novedosas composiciones de vacuna con tos ferina acelular asi como el metodo para su elaboracion
EA201491524A1 (ru) Связывающиеся с эритроцитами терапевтические средства
IN2014KN01713A (es)
IN2014KN01714A (es)
IN2014KN01716A (es)
MX358224B (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer de higado.
NZ714163A (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
BR112016008576A2 (pt) Formulações aquosas estáveis de anticorpos e forma farmacêutica de dosagem unitária
NZ603863A (en) Concentration and lyophilization of influenza vaccine antigens
NZ703581A (en) Anti-cd70 antibody drug conjugates
NZ602220A (en) Antibodies with ph dependent antigen binding
PH12015501519A1 (en) Vaccines with higher carbohydrate antigen density and novel saponin adjuvant
MY169147A (en) Drug-protein conjugates
AR092896A1 (es) Composiciones inmunogenicas
PE20100365A1 (es) Novedosas vacunas de combinacion con tos ferina de celulas enteras y metodo para su elaboracion
NZ606988A (en) Combination pharmaceutical compositions and method of treatment of vertigo, kinetosis and vegetative-vascular dystonia
MX354924B (es) Molecula portadora que comprende un antigeno spr0096 y un spr2021.
WO2011000962A3 (en) Hiv related peptides combination or fusion for use in hiv vaccine composition or as diagnostic means
WO2014004385A3 (en) Anti-cancer vaccines
PE20141515A1 (es) Procedimiento de formulacion de una vacuna que contiene al menos dos antigenos susceptibles de adsorberse en oxihidroxido de aluminio
BR112013023599A2 (pt) método para preparar um conjugado de carboidrato-epítopo de célula-t, conjugado de carboidrato-epítopo de célula-t, e, uso de um conjugado de carboidrato-epítopo de célula-t
TH149877A (th) วิธีสำหรับการผสมสูตรวัคซีนที่มีแอนติเจนอย่างน้อยสองชนิดที่สามารถดูดซับบนอลูมิเนียม ออกซิไฮดรอกไซด์
IN2015DN02993A (es)

Legal Events

Date Code Title Description
FG Grant, registration